A golden year for Wall Street’s Australian stock picker

Matthew McLennan’s $14.5 billion position in gold bars and miners paid off handsomely for First Eagle this year. But he insists the precious metal still has room to run.
Matthew McLennan in his office at First Eagle Investments in New York. Picture: Jaclyn Licht

Jonathan Shapiro

A golden year for Wall Street’s Australian stock picker

July 7, 2025
Matthew McLennan’s $14.5 billion position in gold bars and miners paid off handsomely for First Eagle this year. But he insists the precious metal still has room to run.
Read Transcript

Of all the Australians who have made a name for themselves on Wall Street, Matthew McLennan can surely lay claim to be among the most prominent.

Born in Papua New Guinea and raised in Queensland, McLennan landed in New York via Sydney and London and is now the co-head of First Eagle’s global value team, overseeing the asset manager’s $US62.3 billion ($94.7 billion) global fund.

It’s far from your typical equities fund. In fact, more than 10 per cent of the portfolio is invested, not in stocks, but gold bullion. In addition, the fund has stakes in listed gold miners which lifts its total exposure to the precious metal to more than 14.5 per cent.

And in a year in which gold has been among the hottest commodities, it’s a position that has paid off for investors in the fund, which returned 19.07 per cent in the 12 months to July 1.

“The reason we own gold is it’s the embodiment of scarcity value,” McLennan tells The Australian Financial Review ahead of his appearance at the Sohn Hearts & Minds charity conference in November this year.

“You can create more nominal claims on a sovereign entity, but gold is relatively fixed in supply, and so it’s a good potential hedge against that nominal drift accelerating in the economy.”

In other words, gold is there to protect value in times when central banks are pumping the global economy with money or governments are flooding it with debt.

But is the rally in gold near its peak? McLennan doesn’t think so.

“I would argue that gold has recovered from depressed levels relative to equities, and depressed levels relative to the stock of government debt, to more rational price levels.”

McLennan insists he’s not a “gold bug” and in April amid the market rout, he was trimming the fund’s gold exposure to buy beaten-down stocks.

In fact, the past year has been unusual in that both stocks and gold have enjoyed a solid rally which has meant the precious metal hasn’t just protected the portfolio but enhanced it.

The global sharemarket gained 16.7 per cent, but the gold price jumped 42 per cent and the index of gold miners was even higher at 55.3 per cent.

For McLennan, the dual rise in stocks and gold is a “very important price signal in markets”.

“What it tells you is that the real value of money has gone down. The market is making a judgment that real assets, in aggregate, are worth more, and the symmetry of that is that there’s an expected greater supply of fixed nominal assets.”

By fixed nominal assets, he means bonds, and in particular government bonds. The worry he shares with the market is that we’re getting closer to the limits of how much money governments can borrow, and ultimately repay.

If the 1990s was a crisis in corporate debt, and the 2000s a crisis centred on household debt, “the emergent risk for the decade ahead has been sovereign in nature”.

McLennan is also concerned that United States indebtedness is high at a time when most Americans have jobs, and the country will lack the capacity to borrow what it needs if the economy turns.

In time, the market is going to demand higher interest rates to lend to the government either because inflation goes up or the risk of default or debasement goes up.

“The absence of a risk-free rate is global in nature, and it’s an interesting backdrop for what’s going on in markets at the moment,” the fund manager adds.


Risk of complacency


For now, the market appears to have set aside its worries about how the US will be able to finance its deficit as sharemarkets are back at record highs and corporate debt spreads have contracted to their lowest levels since the global financial crisis.

“When you have easy financial conditions, low credit spreads, high multiples, there’s less asymmetry between price and prospects,” McLennan says.

“Prospects can improve, but you’re already pricing some improvement. So, I think there may be a risk of complacency in risk assets.”

And if the next six months is as eventful as the last, the market’s confidence is set to be shaken again.

“If there’s one commodity, the market’s short of its patience.”

McLennan was first hired at Goldman Sachs in Sydney in 1994 before he eventually found his way to London where he ran a global equity fund for the firm’s private clients.

In September 2008 just as Lehman Brothers was collapsing, and the global financial system was on the brink, McLennan joined First Eagle, a firm with a heritage that dates back to the 1800s.

The timing was hardly ideal, but the real challenge was to come. Because the value style of investing, which can broadly be defined as buying stocks on low valuations, has been out of favour ever since.

Since January 2009, the MSCI value factor has lagged the global index while the MSCI growth factor is 43 per cent ahead.

“The essence of a value mindset is that you see risk as a permanent impairment of capital. For us, our primary objective as investors is to avoid the permanent impairment of capital.”

McLennan says the traditional value investing approach of buying the cheapest stocks based on certain crude measures left investors exposed to “adverse selection risk”. In other words, they may end up owning businesses with weak market positions, vulnerable balance sheets and poor management.

“We have to feel comfortable with a business first before we assess value,” he adds. “Ultimately, you have to feel comfortable that there’s some persistence to the cash flow stream and some integrity to the positional attributes of the business before you can capitalise earnings.”

Among First Eagle’s largest current holdings are Meta, Oracle, HCA Healthcare and Philip Morris.

The 56-year-old has managed to survive and flourish on Wall Street for three decades. So, what’s his secret?

Patience, he says.

“If there’s one commodity, the market’s short of its patience. Having a patient temperament enables you to weather protracted windows where your approach might be short on social acceptance.

“It helps you stick to a philosophy, even though there may be fads in between that lead other people into what turn out to be dead ends.”

Another essential quality in funds management is humility, he adds.

“The reality is that much of what you’ve learned in business school is how to model statistical risk. But the truth is, a complex system like the world economy is much better described by uncertainties.

“You just have to be open-minded to the fact that the reality can be quite strange. If you construct portfolios that can be robust in hard-to-imagine scenarios that gives you some staying power.”

The Sohn Hearts & Minds takes place at the Sydney Opera House on Friday, November 14, 2025. The Australian Financial Review is a media partner and tickets can be purchased here.

This article was originally posted by The Australian Financial Review here.

Licensed by Copyright Agency. You must not copy this work without permission.

Of all the Australians who have made a name for themselves on Wall Street, Matthew McLennan can surely lay claim to be among the most prominent.

Born in Papua New Guinea and raised in Queensland, McLennan landed in New York via Sydney and London and is now the co-head of First Eagle’s global value team, overseeing the asset manager’s $US62.3 billion ($94.7 billion) global fund.

It’s far from your typical equities fund. In fact, more than 10 per cent of the portfolio is invested, not in stocks, but gold bullion. In addition, the fund has stakes in listed gold miners which lifts its total exposure to the precious metal to more than 14.5 per cent.

And in a year in which gold has been among the hottest commodities, it’s a position that has paid off for investors in the fund, which returned 19.07 per cent in the 12 months to July 1.

“The reason we own gold is it’s the embodiment of scarcity value,” McLennan tells The Australian Financial Review ahead of his appearance at the Sohn Hearts & Minds charity conference in November this year.

“You can create more nominal claims on a sovereign entity, but gold is relatively fixed in supply, and so it’s a good potential hedge against that nominal drift accelerating in the economy.”

In other words, gold is there to protect value in times when central banks are pumping the global economy with money or governments are flooding it with debt.

But is the rally in gold near its peak? McLennan doesn’t think so.

“I would argue that gold has recovered from depressed levels relative to equities, and depressed levels relative to the stock of government debt, to more rational price levels.”

McLennan insists he’s not a “gold bug” and in April amid the market rout, he was trimming the fund’s gold exposure to buy beaten-down stocks.

In fact, the past year has been unusual in that both stocks and gold have enjoyed a solid rally which has meant the precious metal hasn’t just protected the portfolio but enhanced it.

The global sharemarket gained 16.7 per cent, but the gold price jumped 42 per cent and the index of gold miners was even higher at 55.3 per cent.

For McLennan, the dual rise in stocks and gold is a “very important price signal in markets”.

“What it tells you is that the real value of money has gone down. The market is making a judgment that real assets, in aggregate, are worth more, and the symmetry of that is that there’s an expected greater supply of fixed nominal assets.”

By fixed nominal assets, he means bonds, and in particular government bonds. The worry he shares with the market is that we’re getting closer to the limits of how much money governments can borrow, and ultimately repay.

If the 1990s was a crisis in corporate debt, and the 2000s a crisis centred on household debt, “the emergent risk for the decade ahead has been sovereign in nature”.

McLennan is also concerned that United States indebtedness is high at a time when most Americans have jobs, and the country will lack the capacity to borrow what it needs if the economy turns.

In time, the market is going to demand higher interest rates to lend to the government either because inflation goes up or the risk of default or debasement goes up.

“The absence of a risk-free rate is global in nature, and it’s an interesting backdrop for what’s going on in markets at the moment,” the fund manager adds.


Risk of complacency


For now, the market appears to have set aside its worries about how the US will be able to finance its deficit as sharemarkets are back at record highs and corporate debt spreads have contracted to their lowest levels since the global financial crisis.

“When you have easy financial conditions, low credit spreads, high multiples, there’s less asymmetry between price and prospects,” McLennan says.

“Prospects can improve, but you’re already pricing some improvement. So, I think there may be a risk of complacency in risk assets.”

And if the next six months is as eventful as the last, the market’s confidence is set to be shaken again.

“If there’s one commodity, the market’s short of its patience.”

McLennan was first hired at Goldman Sachs in Sydney in 1994 before he eventually found his way to London where he ran a global equity fund for the firm’s private clients.

In September 2008 just as Lehman Brothers was collapsing, and the global financial system was on the brink, McLennan joined First Eagle, a firm with a heritage that dates back to the 1800s.

The timing was hardly ideal, but the real challenge was to come. Because the value style of investing, which can broadly be defined as buying stocks on low valuations, has been out of favour ever since.

Since January 2009, the MSCI value factor has lagged the global index while the MSCI growth factor is 43 per cent ahead.

“The essence of a value mindset is that you see risk as a permanent impairment of capital. For us, our primary objective as investors is to avoid the permanent impairment of capital.”

McLennan says the traditional value investing approach of buying the cheapest stocks based on certain crude measures left investors exposed to “adverse selection risk”. In other words, they may end up owning businesses with weak market positions, vulnerable balance sheets and poor management.

“We have to feel comfortable with a business first before we assess value,” he adds. “Ultimately, you have to feel comfortable that there’s some persistence to the cash flow stream and some integrity to the positional attributes of the business before you can capitalise earnings.”

Among First Eagle’s largest current holdings are Meta, Oracle, HCA Healthcare and Philip Morris.

The 56-year-old has managed to survive and flourish on Wall Street for three decades. So, what’s his secret?

Patience, he says.

“If there’s one commodity, the market’s short of its patience. Having a patient temperament enables you to weather protracted windows where your approach might be short on social acceptance.

“It helps you stick to a philosophy, even though there may be fads in between that lead other people into what turn out to be dead ends.”

Another essential quality in funds management is humility, he adds.

“The reality is that much of what you’ve learned in business school is how to model statistical risk. But the truth is, a complex system like the world economy is much better described by uncertainties.

“You just have to be open-minded to the fact that the reality can be quite strange. If you construct portfolios that can be robust in hard-to-imagine scenarios that gives you some staying power.”

The Sohn Hearts & Minds takes place at the Sydney Opera House on Friday, November 14, 2025. The Australian Financial Review is a media partner and tickets can be purchased here.

This article was originally posted by The Australian Financial Review here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by Australian Financial Review, published on Jul 07, 2025. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍
November 6, 2024

Why this New York hedge fund manager sees opportunity in European stocks

Influential New York-hedge fund manager Ricky Sandler will turn to Europe for his next stock pick.

Read More
Vihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie Douvis
November 5, 2024

Antipodes’ Ross says short-term wealth hinges on US election

The portfolio manager says defensive stocks pose a bigger risk than the magnificent seven for investors that are overexposed to the American sharemarket.

Read More
Antipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John Feder
November 5, 2024

Concentration risk key for investors: Antipodes Partners’ Vihari Ross

The concentration risk in global stock indexes that has built up during the strong rise over the past year must now be a key consideration for global investors, according to Vihari Ross.

Read More
JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.
November 5, 2024

The fundie betting big on China – with help from AI

Mr Mehta is sticking to his well-worn strategy: he’s hunting for companies across Asia that aren’t battling intense competition and have management teams focused on costs, cash generation and high payouts to shareholders.

Read More
Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.
October 29, 2024

Why this fundie wants you to ‘wince’ at his stock picks

When fund managers come to pitch their favourite stock at the annual Sohn Hearts & Minds conference, there are two ways they can go: they can play it safe, or they can take a risk and shock the room.

Read More
October 27, 2024

IFM Investors’ Rikki Bannan backs small cap investments to rebound after mixed performance

IFM Investors executive director Rikki Bannan believes this year could be a good one to invest in some select small cap stocks.

Read More
October 22, 2024

Meet the 2024 Conference Managers

Following a global search, the Conference Fund Manager Selection Committee is pleased to share eleven new managers for 2024.

Read More
October 21, 2024

Chris Kourtis is on a winning streak. Here’s his next ASX pick

Chris Kourtis of Ellerston Capital thinks he’s found another winner and thinks it’s the last chance to have a bite at the cherry before the strategy plays out.

Read More
Ellerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta Campion
October 21, 2024

Why Ellerston Capital’s Chris Kourtis plans to back a ‘hated’ stock

Chris Kourtis of Ellerston Capital plans to tip one of the “most hated” stocks in Australia when he presents at the 2024 Sohn Hearts & Minds Conference.

Read More
 ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion
October 14, 2024

Alex Pollak champions rewards of disruptive investment

Alex Pollak’s funds management company Loftus Peak rode the Nvidia wave and he is now looking at more opportunities in disruptive industry stocks.

Read More
October 8, 2024

Sumit Gautam - Why AI won't deliver in 2025 | Scalar Gauge

Sumit Gautam is the Founder of Scalar Gauge and speaks with Equity Mates ahead of his appearance at the Sohn Hearts & Minds conference.

Read More
September 30, 2024

Missed out on Nvidia and Ozempic? This fundie says it’s never too late

Northcape Capital’s Fleur Wright is still kicking herself for not owning market darlings Nvidia and Novo Nordisk, the maker of the weight loss wonder drug Ozempic, before shares of those companies rocketed in 2023.

Read More
September 23, 2024

Scalar Gauge Fund founder Sumit Gautam cautious about over-hyped AI

Tech investor Sumit Gautam carefully avoids the word bubble when describing the investor frenzy surrounding the rise of artificial intelligence, but warns there are dangers of getting caught up in the hype.

Read More
September 9, 2024

The Wellcome Trust’s Nick Moakes made a 100-year bet. It’s paying off

Chief Investment Officer, Nick Moakes raised almost $3 billion at ultra-low rates. Sometimes the long view can be the most profitable.

Read More
Wellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven PocockWellcome Trust chief investment officer Nicholas Moakes. Picture: Steven Pocock
September 5, 2024

Honesty the only policy that matters, says Wellcome Trust’s Nicholas Moakes

The chief investment officer of the London-based $71bn Wellcome Trust, Nick Moakes, has a simple rule for the trust’s investment team: “Never invest with anyone who is or has been or should have been in prison.”

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.